Ozempic legs is an informal term describing visible changes to the appearance of the legs — including loss of fat, muscle, and skin laxity — that some people notice during treatment with semaglutide (Ozempic or Wegovy). The phrase gained traction on social media, where users shared striking before-and-after images following significant weight loss on these medicines. Whilst not a recognised medical diagnosis, the concern is genuine and increasingly common as prescribing rates rise across the UK. This article explains what causes these changes, how they relate to weight loss rather than the drug itself, and what you can do to minimise their impact.

What Is Ozempic Legs and Why Are People Talking About It?

'Ozempic legs' is an informal, colloquial term used to describe visible changes in the appearance of the legs that some people notice during treatment with semaglutide — the active ingredient in Ozempic and Wegovy. The term has spread widely on social media platforms, where users have shared before-and-after photographs showing noticeably thinner, more angular legs following significant weight loss on the medication.

The changes typically involve a reduction in subcutaneous fat in the thighs and calves, leading to increased visibility of underlying structures such as tendons, veins, and bony prominences. In some cases, there is also a degree of muscle loss, which can give the legs a deflated or wasted appearance rather than a toned one.

It is important to understand that these changes are consequences of significant weight loss rather than direct adverse drug reactions caused by semaglutide itself. They can occur with any form of substantial, sustained weight loss.

Whilst 'Ozempic legs' is not a recognised medical diagnosis, it reflects a genuine and understandable concern among patients. In the UK, Ozempic is licensed solely for the management of type 2 diabetes (at doses of 0.5 mg, 1 mg, or 2 mg weekly); it is not licensed for weight loss, and using it for weight management would be off-label. Wegovy (semaglutide 2.4 mg weekly) is the formulation licensed in the UK for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidaemia.^[2] NHS access to Wegovy is governed by NICE Technology Appraisal TA875, which restricts prescribing to specialist weight management services and includes additional clinical criteria.^[2] Both medicines are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). As prescribing rates have increased, so too has public awareness of the cosmetic and physical changes associated with rapid or substantial weight loss on these medicines.

Ozempic Legs, Face and Hands: How Semaglutide Changes Your Appearance

'Ozempic legs' is part of a broader pattern of appearance changes that can affect multiple areas of the body during semaglutide treatment. Similar informal, social-media-derived terms have emerged, including 'Ozempic face' — referring to hollowing of the cheeks, deepening of nasolabial folds, and a gaunt or aged facial appearance — and, less commonly, 'Ozempic hands', which describes thinning of the skin and increased prominence of tendons and veins on the hands. It should be noted that these are descriptive, anecdotal terms; the evidence base is largely observational, and the changes described are not unique to semaglutide.

These changes share a common underlying cause: rapid loss of subcutaneous fat across the body as a result of sustained caloric deficit. Fat is not lost uniformly; the pattern of fat loss is largely determined by genetics, age, sex, and baseline body composition. Some individuals lose a disproportionate amount of fat from the face and extremities, whilst others notice changes primarily in the abdomen or thighs.

The cosmetic impact can be more pronounced in older patients, whose skin has reduced elasticity and is less able to contract following fat loss. This can result in loose or crepey skin on the thighs, upper arms, and around the knees. These changes are not specific to semaglutide — they can occur with any form of significant, sustained weight loss — but the rate at which GLP-1 receptor agonists facilitate weight reduction may make them more noticeable in some individuals.

Why Does Semaglutide Treatment Lead to Leg Muscle Loss and Skin Changes?

Semaglutide works as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking a naturally occurring gut hormone. It enhances insulin secretion in response to elevated blood glucose, suppresses glucagon, and slows gastric emptying. Crucially, it also acts on appetite-regulating centres in the brain, significantly reducing hunger and caloric intake. This sustained caloric deficit drives weight loss.

When the body loses weight rapidly through caloric restriction, it does not draw exclusively on fat stores. Without adequate protein intake and resistance exercise, a proportion of weight lost will come from lean (fat-free) mass, including skeletal muscle. The term 'sarcopenia' refers specifically to age-related muscle loss and should not be used interchangeably with diet-induced lean mass reduction. Body composition data from the STEP 1 trial (using DEXA scanning in a sub-study of participants using semaglutide 2.4 mg) suggest that a meaningful proportion of total weight lost can be lean mass, though the exact proportion varies considerably between individuals and depends on diet quality, physical activity, and baseline body composition. It is also worth noting that, despite some absolute reduction in lean mass, the proportion of body weight that is lean mass may increase overall as fat mass falls more substantially.

In the legs specifically, loss of both subcutaneous fat and muscle mass can produce a visibly thinner, less defined appearance. The skin, which previously conformed to a larger underlying volume, may become loose or saggy, particularly around the inner thighs and knees. Reduced skin elasticity — especially in those over 40 — means the skin does not readily retract, compounding the cosmetic effect.

Leg Pain, Weakness and Other Side Effects: What to Be Aware Of

Some patients report leg pain, muscle cramps, or generalised weakness during semaglutide treatment. These symptoms are not listed as established adverse reactions in the Ozempic or Wegovy Summary of Product Characteristics (SmPC), but may be related to reduced caloric and nutritional intake, dehydration, deconditioning, or loss of lean mass rather than a direct effect of the medicine itself.

The most commonly reported side effects of semaglutide, as documented by the MHRA and EMA, are gastrointestinal in nature and include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These are most pronounced when starting treatment or increasing the dose. Persistent nausea and reduced appetite can contribute to inadequate nutritional intake, which in turn may worsen muscle loss and contribute to fatigue or weakness.

Important red-flag symptoms — seek urgent medical attention:

• Severe abdominal pain, especially if it radiates to the back — this may indicate pancreatitis, a recognised risk with GLP-1 receptor agonists.^[1] Stop semaglutide and seek same-day medical assessment.

• Persistent upper abdominal pain, nausea, or jaundice (yellowing of the skin or eyes) — these may indicate gallbladder disease, including gallstones, which are more common with rapid weight loss.

• Reduced urine output, dizziness, or confusion — these may indicate dehydration and acute kidney injury (AKI), particularly if vomiting or diarrhoea is severe.

• Sudden changes in vision — semaglutide has been associated with worsening of diabetic retinopathy in some patients with type 2 diabetes; any sudden visual disturbance warrants prompt ophthalmological review.^[1][3]

• Severe or persistent leg pain with swelling or redness — this could indicate deep vein thrombosis (DVT). Seek same-day urgent assessment. If you develop chest pain, sudden breathlessness, or cough up blood, call 999 immediately, as these may indicate a pulmonary embolism (PE).

• Significant muscle weakness affecting mobility or daily activities.

Hypoglycaemia: Patients with type 2 diabetes who are also taking insulin or a sulfonylurea (such as gliclazide) should be aware of an increased risk of low blood glucose (hypoglycaemia) when starting semaglutide. Discuss dose adjustments with your prescribing clinician.

Do not stop semaglutide abruptly without medical guidance. Contact your GP, diabetes specialist, or prescribing clinician if you are concerned about any symptoms. Suspected side effects can be reported to the MHRA via the Yellow Card scheme at yellowcard.[1]mhra.gov.uk.

How to Prevent and Manage Ozempic Legs

Whilst it may not be possible to entirely prevent changes in leg appearance during semaglutide treatment, several evidence-based strategies can help minimise lean mass loss, support skin health, and maintain overall physical function.

Protein intake is a priority. The UK Reference Nutrient Intake (RNI) for protein is 0.75 g per kilogram of body weight per day for adults, but higher intakes are commonly recommended during periods of significant weight loss to help preserve lean muscle mass. The appropriate target for an individual will depend on their age, body composition, and clinical circumstances; a registered dietitian can provide personalised guidance. Good dietary sources include lean meat, fish, eggs, dairy, legumes, and plant-based protein foods. The British Dietetic Association (BDA) provides patient-friendly guidance on protein intake.

Resistance exercise is equally important. Strength training — such as weightlifting, bodyweight exercises, or resistance band work — stimulates muscle protein synthesis and helps counteract lean mass loss associated with caloric restriction.^[5] The UK Chief Medical Officers' Physical Activity Guidelines recommend that adults engage in muscle-strengthening activities on at least two days per week. Even light resistance work can make a meaningful difference to body composition outcomes during weight loss.

For skin laxity, options include:

• Staying well hydrated to support skin health

• Gradual weight loss where clinically appropriate, to allow the skin more time to adapt

• Topical moisturisers — some products containing ingredients such as retinol or hyaluronic acid may modestly improve skin texture, though evidence for significant improvement in post-weight-loss skin laxity is limited; expectations should be realistic

• Allowing time for weight to stabilise before assessing the degree of skin laxity, as some improvement may occur naturally

• Referral for excess skin — NHS referral for surgical management of excess skin (such as thigh or arm reduction) is generally restricted to cases where there is a functional problem, such as recurrent skin infections or significant impairment of daily activities. Patients seeking treatment for cosmetic reasons alone would typically need to explore private options. A GP can advise on eligibility.

Patients should discuss any concerns about body composition changes with their prescribing clinician, who can review the treatment plan and refer to appropriate allied health professionals, including a dietitian or physiotherapist.

Ozempic vs Wegovy: Are the Effects on Legs the Same?

Both Ozempic and Wegovy contain semaglutide as their active ingredient, but they are licensed for different indications and used at different doses. Ozempic (0.5 mg, 1 mg, or 2 mg weekly) is licensed in the UK solely for the management of type 2 diabetes and is not licensed for weight loss. Wegovy (up to 2.4 mg weekly) is licensed specifically for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity. NHS access to Wegovy is subject to NICE TA875 criteria, which limit prescribing to specialist weight management services; eligibility criteria apply.^[2] Private prescribing must follow the terms of the marketing authorisation.

Because Wegovy is used at a higher maintenance dose and is prescribed primarily for weight loss, patients using it tend to lose more weight overall. The appearance changes associated with 'Ozempic legs' — and related changes to the face and hands — are best understood as proportional to the degree and rate of weight lost, rather than as a direct dose-dependent effect of semaglutide itself. Greater weight loss, achieved more rapidly, is more likely to result in visible changes to body composition and skin.

The underlying mechanism driving these changes is the same for both medications: sustained caloric deficit leading to loss of fat and, to a variable degree, lean muscle mass. The side effect profiles are broadly similar, with gastrointestinal effects being most common for both. Patients using either medication should receive the same preventive advice regarding protein intake, resistance exercise, and monitoring of body composition.

If you are prescribed either Ozempic or Wegovy and have concerns about changes to your legs or overall appearance, raise these with your GP, diabetes specialist, or weight management team. Both medications are subject to ongoing pharmacovigilance by the MHRA, and any suspected side effects should be reported via the Yellow Card scheme at yellowcard.[1]mhra.gov.uk.

Frequently Asked Questions